Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): protocol for a phase II double-blind randomised controlled feasibility trial.

Michael J R DesboroughRustam Al-Shahi SalmanSimon J StanworthDiane HavardPaul M BrennanRobert A DineenTimothy J CoatsTrish HepburnPhilip M BathNikola Sprigg

Published in: BMJ open (2020)

NCT03696121; ISRCTN67038373; EudraCT 2018-001904-12.

Keyphrases

phase ii
double blind
placebo controlled
clinical trial
study protocol
phase iii
open label
randomized controlled trial
atrial fibrillation
drug induced
blood brain barrier
brain injury